This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Reduction in lipoprotein(a) with PCSK9 monoclonal ...
Journal

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials

Read time: 1 mins
Published:25th Mar 2020
Author: Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA.
Ref.:J Am Coll Cardiol. 2014 Apr 8;63(13):1278-88.
DOI:10.1016/j.jacc.2014.01.006.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest